Business Description
Xlife Sciences AG
ISIN : CH0461929603
Share Class Description:
FRA:XLS: Ordinary SharesTotal Employee Number:
17Description
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -19.66 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.19 | |||||
Beneish M-Score | 5.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -36.1 | |||||
3-Year EPS without NRI Growth Rate | -16.7 | |||||
3-Year FCF Growth Rate | 35.4 | |||||
3-Year Book Growth Rate | 3.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.54 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 47.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 25.62 | |||||
9-Day RSI | 35.9 | |||||
14-Day RSI | 41.17 | |||||
3-1 Month Momentum % | -0.44 | |||||
6-1 Month Momentum % | -10.94 | |||||
12-1 Month Momentum % | 12.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.1 | |||||
Quick Ratio | 0.1 | |||||
Cash Ratio | 0.07 | |||||
Days Inventory | 54.89 | |||||
Days Sales Outstanding | 7952.13 | |||||
Days Payable | 1046.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -4.58 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 3.27 | |||||
Operating Margin % | -11475.27 | |||||
Net Margin % | -7835.27 | |||||
EBITDA Margin % | -1109.82 | |||||
FCF Margin % | -329.79 | |||||
OCF Margin % | -329.79 | |||||
ROE % | -7.22 | |||||
ROA % | -4.06 | |||||
ROIC % | -5.02 | |||||
3-Year ROIIC % | -14.75 | |||||
ROC (Joel Greenblatt) % | -1121.82 | |||||
ROCE % | -6.05 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 7.46 | |||||
PS Ratio | 545.95 | |||||
PB Ratio | 0.41 | |||||
Price-to-Tangible-Book | 3.55 | |||||
EV-to-EBIT | -8.32 | |||||
EV-to-EBITDA | -85.61 | |||||
EV-to-Revenue | 950.13 | |||||
EV-to-FCF | -289.35 | |||||
Price-to-GF-Value | 2.77 | |||||
Price-to-Projected-FCF | 0.7 | |||||
Earnings Yield (Greenblatt) % | -12.02 | |||||
FCF Yield % | -0.78 | |||||
Forward Rate of Return (Yacktman) % | 18.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xlife Sciences AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.292 | ||
| EPS (TTM) (€) | -4.026 | ||
| Beta | 0.106 | ||
| 3-Year Sharpe Ratio | -0.24 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 52.79 | ||
| 14-Day RSI | 41.17 | ||
| 14-Day ATR (€) | 1.35324 | ||
| 20-Day SMA (€) | 24.74 | ||
| 12-1 Month Momentum % | 12.32 | ||
| 52-Week Range (€) | 16.25 - 28.6 | ||
| Shares Outstanding (Mil) | 5.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xlife Sciences AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xlife Sciences AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xlife Sciences AG Frequently Asked Questions
What is Xlife Sciences AG(FRA:XLS)'s stock price today?
The current price of FRA:XLS is €21.60. The 52 week high of FRA:XLS is €28.60 and 52 week low is €16.25.
When is next earnings date of Xlife Sciences AG(FRA:XLS)?
The next earnings date of Xlife Sciences AG(FRA:XLS) is .
Does Xlife Sciences AG(FRA:XLS) pay dividends? If so, how much?
Xlife Sciences AG(FRA:XLS) does not pay dividend.
Press Release
Articles on Xlife Sciences AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers